Jefferies Boosts PT on Celldex Therapeutics (CLDX) to $15

Article Related Press Releases (2) Related Articles (1) Stock Quotes (1) Comments (0)

Jefferies raised its price target on Buy-rated Celldex Therapeutics (NASDAQ: CLDX) from $9 to $15.

The firm comments, "CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously)."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $10.49 yesterday, with a 52 week range of $3.61-$11.24.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Citi Raises PT on Micron Technology (MU) to $19
• Deutsche Bank Starts IHS Inc. (IHS) at Hold
• Wells Fargo Upgrades Tibco Software, Inc. (TIBX) to Outperform; Near a Bottom

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?